

Bioorganic & Medicinal Chemistry Letters Vol. 18, No. 2, 2008

Contents

ARTICLES

Conformationally constrained diketopimelic acid analogues as inhibitors of dihydrodipicolinate synthase pp 460–463
Berin A. Boughton, Renwick C. J. Dobson, Juliet A. Gerrard and Craig A. Hutton*

Carbamate-appended N-alkylsulfonamides as inhibitors of γ -secretase

pp 464-468

Carl P. Bergstrom,* Charles P. Sloan, Wai-Yu Lau, David W. Smith, Ming Zheng, Steven B. Hansel, Craig T. Polson, Jason A. Corsa, Donna M. Barten, Kevin M. Felsenstein and Susan B. Roberts

Structure-activity relationships of carbamate-appended N-alkylsulfonamide γ -secretase inhibitors are reported.

Inhibition of tubulin polymerization by select alkenyldiarylmethanes

pp 469-473

Matthew D. Cullen, Taradas Sarkar, Ernest Hamel, Tracy L. Hartman, Karen M. Watson, Robert W. Buckheit, Jr., Christophe Pannecouque, Erik De Clercq and Mark Cushman*

$$H_3CO$$
 H_3CO
 H_3C



Design and SAR of selective T-type calcium channel antagonists containing a biaryl sulfonamide core

pp 474-478

Jon J. Hangeland,* Daniel L. Cheney, Todd J. Friends, Stephen Swartz, Paul C. Levesque, Adam J. Rich, Lucy Sun, Terry R. Bridal, Leonard P. Adam, Diane E. Normandin, Natesan Murugesan and William R. Ewing

T-type calcium channel antagonists were designed using a protocol involving the program SPROUT constrained by a ComFA-based pharmacophore model. From this exercise, a novel series of potent and selective T-type channel antagonists containing a biaryl sulfonamide core were discovered.

Inhibition of dipeptidyl peptidase-IV (DPP-IV) by atorvastatin

pp 479-484

Tony Taldone, S. William Zito and Tanaji T. Talele*

Atorvastatin was determined to be a competitive inhibitor of DPP-IV with $K_i = 57.8 \pm 2.3 \,\mu\text{M}$.

Anti-Pneumocystis carinii and antiplasmodial activities of primaquine-derived imidazolidin-4-ones

pp 485-488

Nuno Vale, Margaret S. Collins, Jiri Gut, Ricardo Ferraz, Philip J. Rosenthal, Melanie T. Cushion, Rui Moreira and Paula Gomes*

The anti-*Pneumocystis carinii* and antiplasmodial activities of compounds **2** were evaluated and found to be correlated. Cycloheptanone-derived imidazolidin-4-ones **2g**, **2j**–**k** (\mathbb{R}^2 and $\mathbb{R}^3 = -(\mathbb{CH}_2)_6$) were the most active.

1-Aminoindanes as novel motif with potential atypical antipsychotic properties

pp 489-493

James M. Graham,* Linda L. Coughenour, Bridget M. Barr, David L. Rock and Sham S. Nikam

R= alkyls, substituted aryls

As part of an on-going effort to investigate the chemical space requirements for $D_2/5$ - HT_{2A} receptor antagonists as atypical antipsychotics, new 1-aminoindanes were synthesized. The replacement of the heterocycle (oxindole) in ziprasidone with a carbocycle (indane) was well tolerated and found to retain binding affinities for dopamine D_2 , serotonin 5- HT_{2A} , and serotonin 5- HT_{1A} receptors. Such compounds hold promise as a new chemical motif with atypical antipsychotic properties for the treatment of schizophrenia and related disorders.

2-Oxo-tetrahydro-1,8-naphthyridines as selective inhibitors of malarial protein farnesyltransferase and as anti-malarials


pp 494-497

Srinivas Olepu, Praveen Kumar Suryadevara, Kasey Rivas, Kohei Yokoyama, Christophe L. M. J. Verlinde, Debopam Chakrabarti, Wesley C. Van Voorhis and Michael H. Gelb*

IC₅₀ on malaria protein farnesyltransferase down to 1 nM, ED₅₀ on malaria parasites down to 175 nM.



Synthesis and structure–activity relationships of metal–ligand complexes that potently inhibit cell migration pp 498–504 Anwar B. Beshir, Sankar K. Guchhait, José A. Gascón and Gabriel Fenteany*



Compounds with antimigratory activity

Prodrug thiamine analogs as inhibitors of the enzyme transketolase

pp 505-508

Yvan Le Huerou,* Indrani Gunawardana, Allen A. Thomas, Steven A. Boyd, Jason de Meese, Walter deWolf, Steven S. Gonzales, May Han, Laura Hayter, Tomas Kaplan, Christine Lemieux, Patrice Lee, Jed Pheneger, Gregory Poch, Todd T. Romoff, Francis Sullivan, Solly Weiler, S. Kirk Wright and Jie Lin

Synthesis of prodrugs of the transketolase inhibitor 5a and their evaluation in murine pharmacokinetic and pharmacodynamic models.



Non-charged thiamine analogs as inhibitors of enzyme transketolase

pp 509-512

Allen A. Thomas,* J. De Meese, Y. Le Huerou, Steven A. Boyd, Todd T. Romoff, Steven S. Gonzales, Indrani Gunawardana, Tomas Kaplan, Francis Sullivan, Kevin Condroski, Joseph P. Lyssikatos, Thomas D. Aicher, Josh Ballard, Bryan Bernat, Walter DeWolf, May Han, Christine Lemieux, Darin Smith, Solly Weiler, S. Kirk Wright, Guy Vigers and Barb Brandhuber

The synthesis and SAR including structure-based rationale drug design for highly potent non-thiazolium TK antagonists is presented.

X = C, N, or S Y: blocks catalysis



Synthesis of genistein derivatives and determination of their protective effects against vascular endothelial cell damages caused by hydrogen peroxide

pp 513-517

Xiao-Hua Fu, Li Wang, Hong Zhao, Hong-Lin Xiang and Jian-Guo Cao*

A series of novel genistein derivatives were designed and synthesized. Their inhibitory effects were then studied on the hydrogen peroxide induced impairment in human umbilical vein endothelial cells in vitro.

Microwave-assisted synthesis and antimicrobial activities of flavonoid derivatives

pp 518–522

Sherif B. Abdel Ghani, Louise Weaver, Zidan H. Zidan, Hussein M. Ali, C. William Keevil and Richard C. D. Brown*

A series of simple synthetic flavonoid derivatives were found to have significant antifungal activity. Two of the compounds also displayed antibacterial activity against methicillin-resistant *Staphylococcus aureus*.

MeO
$$IC_{50}$$
 = 69.6 μ g/mL IC_{50} = 28.2 μ g/mL $(Aspergillus niger)$




Antiproliferative effects of dibenzocyclooctadiene lignans isolated from *Schisandra chinensis* in human cancer cells

pp 523-526

Hye-Young Min, Eun-Jung Park, Ji-Young Hong, You-Jin Kang, Sun-Jack Kim, Hwa-Jin Chung, Eun-Rhan Woo, Tran Manh Hung, Ui Jung Youn, Yeong Shik Kim, Sam Sik Kang, KiHwan Bae and Sang Kook Lee*

Dibenzocyclooctadiene lignans isolated from *Schisandra chinensis* showed antiproliferative effects in various human cancer cells. The methoxy groups at C-3, C-4, C-3', and C-4', the hydroxyl group at C-8', and the stereo-configuration of the biphenyl ring and the angeloyl group might have influence on these activities. Additional studies indicate that one of mechanism of action of an active compound schizantherin C in A549 human lung cancer cells was related to the inhibition of cell cycle progression in G0/G1 phase.



Design and synthesis of novel potent and selective integrin $\alpha_v \beta_3$ antagonists—Novel synthetic routes to isoquinolinone, benzoxazinone, and quinazolinone acetates

pp 527-531

Werner Seitz, Hervé Geneste,* Gisela Backfisch, Jürgen Delzer, Claudia Graef, Wilfried Hornberger, Andreas Kling, Thomas Subkowski and Norbert Zimmermann

An unexpected ring contraction of benzazepinone based $\alpha_v \beta_3$ antagonists led to the design of quinolinone-type derivatives (X = CH₂, O, NH). Novel and efficient synthetic routes to isoquinolinone, benzoxazinone, and quinazolinone acetates were established. Nanomolar $\alpha_v \beta_3$ antagonists based on these new scaffolds were prepared. Moreover, benzoxazinones (X = O) **15a** and **15b** exhibited high microsomal stability and good permeability.

Q = 1,4-Ph, 1,4-Cyclohex. X = CH₂, O, NH



Design, synthesis, and biological evaluation of human sialidase inhibitors. Part 1: Selective inhibitors of lysosomal sialidase (NEU1)

pp 532-537

Sadagopan Magesh,* Setsuko Moriya, Tohru Suzuki, Taeko Miyagi, Hideharu Ishida and Makoto Kiso*

The synthesis and human sialidase inhibitory activities of some amide-linked C9 modified DANA analogues 10a-i are described.

Synthesis and antimycobacterial evaluation of new trans-cinnamic acid hydrazide derivatives

pp 538-541

Samir A. Carvalho,* Edson F. da Silva, Marcus V. N. de Souza, Maria C. S. Lourenço and Felipe R. Vicente

The present article describes a series of ten new *trans*-cinnamic acid hydrazide derivatives, which were synthesized and evaluated for their in vitro antibacterial activity against *Mycobacterium tuberculosis*.

Binding free energy calculation for duocarmycin/DNA complex based on the QPLD-derived partial charge model

pp 542-545

Haizhen Zhong, Karl N. Kirschner, Moses Lee and J. Phillip Bowen*

$$\begin{array}{c} & & & & & & & & & \\ & & & & & & & \\ & & & & & & \\ & & & & & \\ & & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ &$$

(+)-Duocarmycin (DSA)

Substituted oxazolidinones as novel NPC1L1 ligands for the inhibition of cholesterol absorption

pp 546-553

Jeffrey A. Pfefferkorn,* Scott D. Larsen, Chad Van Huis, Roderick Sorenson, Tom Barton, Thomas Winters, Bruce Auerbach, Chenyan Wu, Thaddeus J. Wolfram, Hongliang Cai, Kathleen Welch, Nadia Esmaiel, JoAnn Davis, Richard Bousley, Karl Olsen, Sandra Bak Mueller and Thomas Mertz

This manuscript describes the synthesis and evaluation of a series of oxazolidinone-based NPC1L1 ligands for the inhibition of cholesterol absorption.

Novel indole-3-sulfonamides as potent HIV non-nucleoside reverse transcriptase inhibitors (NNRTIs)


pp 554-559

Zhijian Zhao,* Scott E. Wolkenberg, Meiqing Lu, Vandna Munshi, Gregory Moyer, Meizhen Feng, Anthony V. Carella, Linda T. Ecto, Lori J. Gabryelski, Ming-Tain Lai, Sridar G. Prasad, Youwei Yan, Georgia B. McGaughey, Michael D. Miller, Craig W. Lindsley, George D. Hartman, Joseph P. Vacca and Theresa M. Williams

Conversion of an MMP-potent scaffold to an MMP-selective HER-2 sheddase inhibitor via scaffold hybridization and subtle P1' permutations

pp 560-564


David M. Burns,* Chunhong He, Yanlong Li, Peggy Scherle, Xiangdong Liu, Cindy A. Marando, Mayanne B. Covington, Gengjie Yang, Max Pan, Sharon Turner, Jordan S. Fridman, Gregory Hollis, Kris Vaddi, Swamy Yeleswaram, Robert Newton, Steve Friedman, Brian Metcalf and Wenqing Yao



Targeting RNA with cysteine-constrained peptides

pp 565-567

Virginia A. Burns, Benjamin G. Bobay, Anne Basso, John Cavanagh* and Christian Melander*



Non poly-cationic cyclic peptides that target RNA are presented.

Synthesis and SAR of novel 1,1-dialkyl-2(1H)-naphthalenones as potent HCV polymerase inhibitors

pp 568-570

Todd D. Bosse,* Daniel P. Larson, Rolf Wagner, Doug K. Hutchinson, Todd W. Rockway, Warren M. Kati, Yaya Liu, Sherie Masse, Tim Middleton, Hongmei Mo, Debra Montgomery, Wen Jiang, Gennadiy Koev, Dale J. Kempf and Akhter Molla

The synthesis and SAR of a series of novel 1,1-dialkyl-2(1*H*)-naphthalenones as potent HCV polymerase inhibitors is reported.



Synthesis and structure–activity relationship studies of tyrosine-based antagonists at the human $P2X_7$ receptor

pp 571-575

Ga Eun Lee, Bhalchandra V. Joshi, Wangzhong Chen, Lak Shin Jeong, Hyung Ryong Moon, Kenneth A. Jacobson and Yong-Chul Kim*

From rigid cyclic templates to conformationally stabilized acyclic scaffolds. Part I: The discovery of CCR3 antagonist development candidate BMS-639623 with picomolar inhibition potency against eosinophil chemotaxis

pp 576–585

Joseph B. Santella, III, Daniel S. Gardner, Wenqing Yao, Chongsheng Shi, Prabhakar Reddy, Andrew J. Tebben, George V. DeLucca, Dean A. Wacker, Paul S. Watson, Patricia K. Welch, Eric A. Wadman, Paul Davies, Kimberly A. Solomon, Dani M. Graden, Swamy Yeleswaram, Sandhya Mandlekar, Ilona Kariv, Carl P. Decicco, Soo S. Ko, Percy H. Carter and John V. Duncia*


Conformational analysis of *trans*-1,2-disubstituted cyclohexane CCR3 antagonist **2** revealed that the cyclohexane linker could be replaced by an acyclic *syn*- α -methyl- β -hydroxypropyl linker. It was found that the α -methyl group lowered protein binding and the β -hydroxyl group lowered affinity for CYP2D6. Urea **31** (BMS-639623) with a chemotaxis IC₅₀ = 38 pM for eosinophils was chosen to enter clinical development.

From rigid cyclic templates to conformationally stabilized acyclic scaffolds. Part II: Acyclic replacements for the (3S)-3-benzylpiperidine in a series of potent CCR3 antagonists

pp 586-595

Daniel S. Gardner, Joseph B. Santella, III, Andrew J. Tebben, Douglas G. Batt, Soo S. Ko, Sarah C. Traeger, Patricia K. Welch, Eric A. Wadman, Paul Davies, Percy H. Carter and John V. Duncia*

Conformational analysis of the 3-benzylpiperidine in CCR3 antagonist clinical candidate 1 (BMS-639623) predicts that the benzylpiperidine may be replaced by acyclic, conformationally stabilized, *anti*-1,2-disubstituted phenethyl- and phenpropylamines. Ab initio calculations, enantioselective syntheses, and evaluation in CCR3 binding and chemotaxis assays of *anti*-1-methyl-2-hydroxyphenethyl- and phenpropylamine-containing CCR3 antagonists support this conformational correlation.



1-(2-Phenoxyphenyl)methanamines: SAR for dual serotonin/noradrenaline reuptake inhibition, metabolic stability and hERG affinity

pp 596-599

Gavin A. Whitlock,* Julian Blagg and Paul V. Fish

A novel series of 1-(2-phenoxyphenyl)methanamines are disclosed, which possess selective dual 5-HT and NA reuptake pharmacology. Analogues with good human in vitro metabolic stability, hERG selectivity and passive membrane permeability were identified.

5-HT IC_{50} 8nM NA IC_{50} 32nM DA IC_{50} >4000nM

HLM Clint 15μl/min/mg hERG Ki >7.5μM PAMPA Papp 15 x10⁻⁶cm/sec

A method for the synthesis of an oseltamivir PET tracer

pp 600-602

Masataka Morita, Toshihiko Sone, Kenzo Yamatsugu, Yoshihiro Sohtome, Shigeki Matsunaga, Motomu Kanai,* Yasuyoshi Watanabe and Masakatsu Shibasaki

Discovery of 4-aryl-4H-chromenes as a new series of apoptosis inducers using a cell- and caspase-based HTS assay. Part 5: Modifications of the 2- and 3-positions

pp 603-607

William Kemnitzer, Songchun Jiang, Yan Wang, Shailaja Kasibhatla, Candace Crogan-Grundy, Monica Bubenik, Denis Labrecque, Real Denis, Serge Lamothe, Giorgio Attardo, Henriette Gourdeau, Ben Tseng, John Drewe and Sui Xiong Cai*

The synthesis and SAR of a group of apoptosis inducing 4-aryl-4H-chromenes with modifications at the 2- and 3-positions are reported.

Design and optimization of imidazole derivatives as potent CXCR3 antagonists

pp 608–613

Xiaohui Du, Xiaoqi Chen, Jeffrey T. Mihalic, Jeffrey Deignan, Jason Duquette, An-Rong Li, Bryan Lemon, Ji Ma, Shichang Miao, Karen Ebsworth, Timothy J. Sullivan, George Tonn, Tassie L. Collins and Julio C. Medina*

A series of imidazole derivatives have been designed and optimized for CXCR3 antagonism, pharmacokinetic properties, and reduced formation of glutathione conjugates.

Rapid novel divergent synthesis and muscarinic agonist profile of all four optical isomers of N,N,N-trimethyl(6-methyl-1,4-dioxan-2-yl)methanaminium iodide

Alessandro Piergentili,* Wilma Quaglia, Mario Giannella, Fabio Del Bello, Michela Buccioni, Marta Nesi and Rosanna Matucci

pp 614–618

Structure-based design and synthesis of novel macrocyclic pyrazolo[1,5-a] [1,3,5]triazine compounds as potent inhibitors of protein kinase CK2 and their anticancer activities

pp 619-623

Zhe Nie, Carin Perretta, Philip Erickson, Stephen Margosiak, Jia Lu, April Averill, Robert Almassy and Shaosong Chu*

A series of macrocyclic derivatives has been designed and synthesized based on the X-ray co-crystal structures of pyrazolo[1,5-a] [1,3,5]triazines with corn CK2 (cCK2) protein. Bioassays demonstrated that these macrocyclic pyrazolo[1,5-a] [1,3,5]triazine compounds are potent CK2 inhibitors with K_i around 1.0 nM and they strongly inhibit cancer cell growth with IC₅₀ as low as ~100 nM.

Potency and selectivity of P2/P3-modified inhibitors of cysteine proteases from trypanosomes

pp 624-628

Priyadarshini Jaishankar, Elizabeth Hansell, Dong-Mei Zhao, Patricia S. Doyle, James H. McKerrow and Adam R. Renslo*

A systematic study of P2 and P3 substitution in a series of vinyl sulfone cysteine protease inhibitors is described. The introduction of a methyl substituent in the P2 phenylalanine aryl ring had a favorable effect on protease inhibition and conferred modest selectivity for rhodesain over cruzain. Rhodesain selectivity could be enhanced further by combining these P2 modifications with certain P3 amide substituents.

$$\begin{array}{c|c}
P2 & P1' \\
\hline
N & N & N & SO_2Ph \\
\hline
P3 & K-777 & P1
\end{array} \Rightarrow \begin{array}{c}
P1' & N & SO_2Ph \\
\hline
P1 & N & N & SO_2Ph \\
\hline
P1 & N & N & SO_2Ph \\
\hline
P1 & N & N & SO_2Ph \\
\hline
P1 & N & N & SO_2Ph \\
\hline
P1 & N & N & SO_2Ph \\
\hline
P2 & N & N & N & SO_2Ph \\
\hline
P3 & K-777 & P1 & N & SO_2Ph \\
\hline
P4 & N & N & N & SO_2Ph \\
\hline
P5 & N & N & N & SO_2Ph \\
\hline
P6 & N & N & N & SO_2Ph \\
\hline
P7 & N & N & N & SO_2Ph \\
\hline
P8 & N & N & N & SO_2Ph \\
\hline
P9 & N & N & N & SO_2Ph \\
\hline
P1 & N & N & SO_2Ph \\
\hline
P1 & N & N & SO_2Ph \\
\hline
P2 & N & N & N & SO_2Ph \\
\hline
P3 & N & N & N & SO_2Ph \\
\hline
P4 & N & N & SO_2Ph \\
\hline
P5 & N & N & N & SO_2Ph \\
\hline
P6 & N & N & N & SO_2Ph \\
\hline
P7 & N & N & SO_2Ph \\
\hline
P8 & N & N & N & SO_2Ph \\
\hline
P9 & N & N & N & SO_2Ph \\
\hline
P9 & N & N & N & SO_2Ph \\
\hline
P1 & N & N & N & SO_2Ph \\
\hline
P1 & N & N & N & SO_2Ph \\
\hline
P2 & N & N & N & N & SO_2Ph \\
\hline
P3 & N & N & N & N & N & N \\
\hline
P4 & N & N & N & N & N & N \\
\hline
P5 & N & N & N & N & N & N \\
\hline
P6 & N & N & N & N & N & N \\
\hline
P7 & N & N & N & N & N & N \\
\hline
P8 & N & N & N & N & N & N \\
\hline
P9 & N & N & N & N & N & N \\
\hline
P1 & N & N & N & N & N & N \\
\hline
P1 & N & N & N & N & N & N \\
\hline
P1 & N & N & N & N & N & N \\
\hline
P1 & N & N & N & N & N & N \\
\hline
P1 & N & N & N & N & N & N \\
\hline
P1 & N & N & N & N & N & N \\
\hline
P1 & N & N & N & N & N & N \\
\hline
P1 & N & N & N & N & N & N \\
\hline
P1 & N & N & N & N & N & N \\
\hline
P1 & N & N & N & N & N & N \\
\hline
P1 & N & N & N & N & N & N \\
\hline
P1 & N & N & N & N & N & N \\
\hline
P1 & N & N & N & N & N & N \\
\hline
P1 & N & N & N & N & N & N \\
\hline
P2 & N & N & N & N & N & N \\
\hline
P3 & N & N & N & N & N & N \\
\hline
P4 & N & N & N & N & N & N \\
\hline
P5 & N & N & N & N & N & N \\
\hline
P6 & N & N & N & N & N \\
\hline
P6 & N & N & N & N & N & N \\
\hline
P6 & N & N & N & N & N \\
\hline
P7 & N & N & N & N & N \\
\hline
P7 & N & N & N & N & N \\
\hline
P8 & N & N & N & N & N \\
\hline
P9 & N & N & N & N & N \\
\hline
P9 & N & N & N & N & N \\
\hline
P9 & N & N & N & N & N \\
\hline
P9 & N & N & N & N & N \\
\hline
P9 & N & N & N & N & N \\
\hline
P9 & N & N & N & N & N \\
\hline
P9 & N & N & N & N & N \\
\hline
P9 & N & N & N & N & N \\
\hline
P9 & N & N & N & N & N \\
\hline
P9 & N & N & N & N & N \\
\hline
P9 & N & N & N$$

Development of CXCR3 antagonists. Part 4: Discovery of 2-amino-(4-tropinyl)quinolines

pp 629-633

Roland L. Knight,* Daniel R. Allen, Helen L. Birch, Gayle A. Chapman, Frances C. Galvin, Louise A. Jopling, Christopher J. Lock, Johannes W. G. Meissner, David A. Owen, Gilles Raphy, Robert J. Watson and Sophie C. Williams

The synthesis and biological evaluation of a novel series of 2-aminoquinoline substituted piperidines and tropanes incorporating a homotropene moiety is herein described. The series exhibits potent antagonism of the CXCR3 receptor and superior physicochemical properties. Compound **24d** was found to be orally bioavailable, and PK/PD studies suggested it as a suitable tool for studying the role of CXCR3 in models of disease.

Identification of 2-amino-5-(thioaryl)thiazoles as inhibitors of nerve growth factor receptor TrkA

pp 634-639

Soong-Hoon Kim,* John S. Tokarski, Kenneth J. Leavitt, Brian E. Fink, Mark E. Salvati, Robert Moquin, Mary T. Obermeier, George L. Trainor, Gregory G. Vite, Linda K. Stadnick, Jonathan S. Lippy, Dan You, Matthew V. Lorenzi and Ping Chen

2-Amino-5-(thioaryl)thiazaoles are potent inhibitors of TrkA (e.g., 20h, TrkA IC₅₀ = 0.6 nM) that show anti-proliferative effect in cellular assays. A proposed inhibitor binding mode to TrkA active site is consistent with key SAR observations.

(Phenylpiperazinyl)cyclohexylureas: Discovery of $\alpha_{1a/1d}$ -selective adrenergic receptor antagonists for the treatment of benign prostatic hyperplasia/lower urinary tract symptoms (BPH/LUTS)

pp 640-644

George Chiu,* Shengjian Li, Peter J. Connolly, Virginia Pulito, Jingchun Liu and Steven A. Middleton

A series of (phenylpiperazinyl)cyclohexylureas that show selectivity to human $\alpha_{1a/1d}$ adrenergic receptors were developed. These compounds have potential for the treatment of BPH/LUTS.



Block of cyclic nucleotide-gated channels by tetracaine derivatives: Role of apolar interactions at two distinct locations

pp 645-649

Timothy Strassmaier, Sarah R. Kirk, Tapasree Banerji and Jeffrey W. Karpen*

$$\begin{array}{c|c} & & & \\ &$$

A novel biotinylated diazirinyl ceramide analogue for photoaffinity labeling

pp 650-652

Makoto Hashimoto* and Yasumaru Hatanaka

Novel heterocycle-substituted pyrimidines as inhibitors of NF- κB transcription regulation related to TNF- α cytokine release

pp 653-656

Hyung-Ho Ha, Jee Seon Kim and B. Moon Kim*

22, NF-kB, IC_{50} = 1.4 μ M


Novel heterocyclic ring-substituted pyridines have been designed as inhibitors of glycogen synthase kinase- 3β and compound 22 exhibited good GSK- 3β and NF- κ B inhibition as well as desirable cellular activity.

Preparation of C₆₀-based active esters and coupling of C₆₀ moiety to amines or alcohols

pp 657-660

Hiroki Tsumoto, Katsumasa Takahashi, Takayoshi Suzuki, Hidehiko Nakagawa,

Kohfuku Kohda and Naoki Miyata*



We report the synthesis of C_{60} -based active esters and the coupling of their C_{60} moiety to various amines or alcohols.

A flavonoid gossypin binds to cyclin-dependent kinase 2

pp 661-664

Hojung Kim, Eunjung Lee, Jihye Kim, Bora Jung, Youhoon Chong, Joong-Hoon Ahn and Yoongho Lim*


In order to find flavonoids showing cyclin-dependent kinase 2 (CDK2) binding effects, 347 flavonoid derivatives were docked into the crystal structure of the CDK2. The docking study showed that gossypin has a good conformational match with CDK2, which was confirmed by the binding affinity assay using NMR experiments. In order to find flavonoids showing cyclindependent kinase 2 (CDK2) binding effects, 347 flavonoid derivatives were docked into the crystal structure of the CDK2. The docking study showed that gossypin has a good conformational match with CDK2, which was confirmed by the binding affinity assay using NMR experiments.



Complexation of single strand telomere and telomerase RNA template polyanions by deoxyribonucleic guanidine (DNG) polycations: Plausible anticancer agents

pp 665-669

Xiaohua Zhang and Thomas C. Bruice*




Modifying the glycosidic linkage in digitoxin analogs provides selective cytotoxins

pp 670-673

Joseph M. Langenhan,* Jeffery M. Engle, Lauren K. Slevin, Lindsay R. Fay, Ryan W. Lucker, Kyle R. Smith and Matthew M. Endo

For the first time a panel of linkage-diversified neoglycosides was constructed. This panel of digitoxin analogs included potent and selective tumor cytotoxins; cytotoxicity was dependent on the structure of the glycosidic linkage.



A new series of neutral 5-substituted 4-anilinoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinase

pp 674–678


Bernard Barlaam,* Peter Ballard, Robert H. Bradbury, Richard Ducray, Hervé Germain, D. Mark Hickinson, Kevin Hudson, Jason G. Kettle, Teresa Klinowska, Françoise Magnien, Donald J. Ogilvie, Annie Olivier, Stuart E. Pearson, James S. Scott, Abid Suleman, Cath B. Trigwell, Michel Vautier, Robin D. Whittaker and Robin Wood

Starting from initial lead 1 containing a basic 5-substituent, optimisation of the glycolamide-derived neutral 5-substituent led to potent inhibitors of erbB2 with good pharmacokinetics. Representative compounds 19 and 21 inhibited phosphorylation of erbB2 in a mouse BT474C xenograft model after oral administration.

A highly efficient route to enantiomerically pure $L-N-Bz-Pmp(t-Bu)_2-OH$ and incorporation into a peptide-based protein tyrosine phosphatase inhibitor

pp 679-681

Caitlin E. Hubbard and Amy M. Barrios*




A new class of bradykinin B_1 receptor antagonists with high oral bioavailability and minimal PXR activity

pp 682-687

Dong-Mei Feng, Robert M. DiPardo, Jenny M. Wai, Ronald K. Chang, Christina N. Di Marco, Kathy L. Murphy, Richard W. Ransom, Duane R. Reiss, Cuyue Tang, Thomayant Prueksaritanont, Douglas J. Pettibone, Mark G. Bock and Scott D. Kuduk*

The design and synthesis of a novel class of human bradykinin B₁ antagonists featuring difluoroethyl ether and isoxazole carboxamide moieties are disclosed.



Optimization of the heterocyclic core of the quinazolinone-derived CXCR3 antagonists

pp 688-693

An-Rong Li, Michael G. Johnson, Jiwen Liu, Xiaoqi Chen, Xiaohui Du, Jeffrey T. Mihalic, Jeffrey Deignan, Darin J. Gustin, Jason Duquette, Zice Fu, Liusheng Zhu, Andrew P. Marcus, Phillipe Bergeron, Lawrence R. McGee, Jay Danao, Bryan Lemon, Teresa Carabeo, Timothy Sullivan, Ji Ma, Liang Tang, George Tonn, Tassie L. Collins and Julio C. Medina*

α,β -Cyclic- β -benzamido hydroxamic acids: Novel templates for the design, synthesis, and evaluation of selective inhibitors of TNF- α converting enzyme (TACE)

pp 694-699

Gregory R. Ott,* Naoyuki Asakawa, Zhonghui Lu, Rui-Qin Liu, Maryanne B. Covington, Krishna Vaddi, Mingxin Qian, Robert C. Newton, David D. Christ, James M. Traskos,


Carl P. Decicco and James J.-W. Duan

Selective inhibitors of TNF- α Converting Enzyme (TACE) based on novel α,β -cyclic- β -benzamido hydroxamic acids have been synthesized and evaluated.

Glycopolydiacetylene nanoparticles as a chromatic biosensor to detect Shiga-like toxin producing *Escherichia coli* O157:H7

pp 700-703

Jon O. Nagy,* Yalong Zhang, Wen Yi, Xianwei Liu, Edwin Motari, Jing Catherine Song, Jeffrey T. Lejeune and Peng George Wang*



(i)+

Structural analogs of tylophora alkaloids may not be functional analogs

pp 704-709

Wenli Gao, Annie Pei-Chun Chen, Chung-Hang Leung, Elizabeth A. Gullen, Alois Fürstner, Qian Shi, Linyi Wei, Kuo-Hsiung Lee and Yung-Chi Cheng*



Design, synthesis and evaluation of trifluoromethane sulfonamide derivatives as new potent and selective peroxisome proliferator-activated receptor α agonists

pp 710-715

Nicolas Faucher,* Paul Martres, Alain Laroze, Olivier Pineau, Florent Potvain and Didier Grillot

Starting from the structure of 5, a two-step strategy was applied to identify a new generation of trifluoromethane sulfonamides as potent PPAR α agonists. Synthesis, in vitro and in vivo evaluation of the most potent compound 20 are reported.



α-Hydroxy amides as a novel class of bradykinin B₁ selective antagonists

pp 716-720

Michael R. Wood,* Kathy M. Schirripa, June J. Kim,
Scott D. Kuduk, Ronald K. Chang, Christina N. Di Marco,
Robert M. DiPardo, Bang-Lin Wan, Kathy L. Murphy, Richard W. Ransom,
Raymond S. L. Chang, Marie A. Holahan, Jacquelynn J. Cook, Wei Lemaire,
Scott D. Mosser, Rodney A. Bednar, Cuyue Tang, Thomayant Prueksaritanont,
Audrey A. Wallace, Qin Mei, Jian Yu, Dennis L. Bohn, Frank C. Clayton,
Emily D. Adarayn, Gary R. Sitko, Yvonne M. Leonard, Roger M. Freidinger,
Douglas J. Pettibone and Mark G. Bock

Design and synthesis of substituted 4-oxo-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine-2-carboxamides, novel HIV-1 integrase inhibitors

pp 721–725

H. Marie Langford,* Peter D. Williams, Carl F. Homnick, Joseph P. Vacca, Peter J. Felock, Kara A. Stillmock, Marc V. Witmer, Daria J. Hazuda, Lori J. Gabryelski and William A. Schleif

A series of 4-oxo-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine-2-carboxamides was synthesized and tested for their inhibition of HIV-1 integrase catalytic activity and HIV-1 replication in cells. Structure–activity studies around lead compound 5 indicated that a coplanar relationship of metal-binding heteroatoms provides optimal binding to the integrase active site. Identification of potency-enhancing substituents and adjustments in lipophilicity provided 17b which inhibits integrase-catalyzed strand transfer with an IC50 value of 74 nM and inhibits HIV-1 replication in cell culture in the presence of 50% normal human serum with an IC95 value of 63 nM.

Optimization of biaryl Selective HDAC1&2 Inhibitors (SHI-1:2)

pp 726-731

David J. Witter,* Paul Harrington, Kevin J. Wilson, Melissa Chenard, Judith C. Fleming, Brian Haines, Astrid M. Kral, J. Paul Secrist and Thomas A. Miller

A class of biaryl benzamides was identified and optimized as selective HDAC1&2 inhibitors (SHI-1:2). SAR development based on an initial lead led to a series of potent and selective inhibitors with reduced off-target activity and tumor growth inhibition activity in a HCT-116 xenograft model.

Thiol-based angiotensin-converting enzyme 2 inhibitors: P^1 modifications for the exploration of the S^1 subsite

pp 732–737

David N. Deaton,* Enoch N. Gao, Kevin P. Graham, Jeffrey W. Gross, Aaron B. Miller and John M. Strelow

Screening of a metalloprotease library led to the identification of a thiol-based dual ACE/NEP inhibitor as a potent ACE2 inhibitor. Modifications of the P^1 benzyl moiety led to improvements in ACE2 potency as well as to increased selectivity versus ACE and NEP.



Discovery of 3-aryl-3-methyl-1H-quinoline-2,4-diones as a new class of selective 5-HT $_6$ receptor antagonists


pp 738-743

Churl Min Seong,* Woo Kyu Park, Chul Min Park, Jae Yang Kong and No Sang Park

A series of 3-methyl-3-phenyl-1H-quinoline-2,4-diones was prepared and evaluated for 5-HT $_6$ receptor antagonistic activity.



The first steps. The attack on the carbonyl carbon of pyridoxal cofactor in pyridoxal-dependent enzymes pp 744–748 Philip E. Sonnet, Linda M. Mascavage and David R. Dalton*



Structure-activity relationship and pharmacokinetic profile of 5-ketopyrazole factor Xa inhibitors

pp 749-754

Jeffrey G. Varnes, Dean A. Wacker,* Donald J. P. Pinto, Michael J. Orwat, Jay P. Theroff, Brian Wells, Robert A. Galemo, Joseph M. Luettgen, Robert M. Knabb, Steven Bai, Kan He, Patrick Y. S. Lam and Ruth R. Wexler

$$H_2N$$

N

N

O

 $fXa K_i = 0.11 nM$

Calcitonin gene-related peptide (CGRP) receptor antagonists: Investigations of a pyridinone template


pp 755-758

Diem N. Nguyen,* Daniel V. Paone, Anthony W. Shaw, Christopher S. Burgey, Scott D. Mosser, Victor Johnston, Christopher A. Salvatore, Yvonne M. Leonard, Cynthia M. Miller-Stein, Stefanie A. Kane, Kenneth S. Koblan, Joseph P. Vacca, Samuel L. Graham and Theresa M. Williams

Synthesis and analysis of stabilizing ligands for FKBP-derived destabilizing domains

pp 759-761

Joshua S. Grimley, Denise A. Chen, Laura A. Banaszynski and Thomas J. Wandless*



We recently engineered mutants of the FKBP12 protein that are rapidly degraded when expressed in cells. Shield-2 binds to destabilizing domains (DDs) and provides dose-dependent control of their expression levels.



Synthesis and biological activity of phosphatidylinositol-3,4,5-trisphosphorothioate

pp 762-766


Honglu Zhang, Yong Xu, Nicolas Markadieu, Renaud Beauwens, Christophe Erneux and Glenn D. Prestwich*

(i)+

Acylguanidine inhibitors of β -secretase: Optimization of the pyrrole ring substituents extending into the S1' substrate binding pocket

pp 767-771

Lee D. Jennings,* Derek C. Cole, Joseph R. Stock, Mohani N. Sukhdeo, John W. Ellingboe, Rebecca Cowling, Guixian Jin, Eric S. Manas, Kristi Y. Fan, Michael S. Malamas, Boyd L. Harrison, Steve Jacobsen, Rajiv Chopra, Peter A. Lohse, William J. Moore, Mary-Margaret O'Donnell, Yun Hu, Albert J. Robichaud, M. James Turner, Erik Wagner and Jonathan Bard



A novel series of acyl guanidines with substituents extending into the S1' substrate binding pocket result in small molecule BACE-1 inhibitors with submicromolar potency and moderate to high selectivity for BACE-1 over cathepsin D.

Ohioensins F and G: Protein tyrosine phosphatase 1B inhibitory benzonaphthoxanthenones from the Antarctic moss *Polytrichastrum alpinum*

pp 772–775

Changon Seo, Yun-Hyeok Choi, Jae Hak Sohn, Jong Seog Ahn, Joung Han Yim, Hong Kum Lee and Hyuncheol Oh*

Ohioensins F and G were isolated from *Polytruchastrum alpinum* and evaluated for their PTP1B inhibitory activities.

Design, synthesis and antimalarial activity of benzene and isoquinoline sulfonamide derivatives

pp 776-781

Maloy Kumar Parai, Gautam Panda,* Kumkum Srivastava and Sunil Kumar Puri


$$R^{1} \xrightarrow{\begin{array}{c} 0 \\ N \\ N \\ H \end{array}} \xrightarrow{\begin{array}{c} 0 \\ N \\ H \end{array}} R^{2} = H, CH_{3}, NO_{2}$$

$$R^{1} \xrightarrow{\begin{array}{c} 0 \\ N \\ N \end{array}} \xrightarrow{\begin{array}{c} 0 \\ N \end{array}} \xrightarrow{\begin{array}{c} 0 \\ N \end{array}} \xrightarrow{\begin{array}{c} 0 \\ N \\ N \end{array}} \xrightarrow{\begin{array}{c} 0 \\ N \end{array}} \xrightarrow{\begin{array}{$$



Design, synthesis, and biological activity of piperidine diamine derivatives as factor Xa inhibitor Akiyoshi Mochizuki,* Yumi Nakamoto, Hiroyuki Naito, Kouichi Uoto and Toshiharu Ohta

pp 782–787



Potent Inhibitory and Anticoagulant Activity

An efficient, simple and expedition synthesis of 1-amidoalkyl-2-naphthols as 'drug like' molecules for biological screening

pp 788-792

Hamid Reza Shaterian,* Hossein Yarahmadi and Majid Ghashang

An efficient and direct protocol for the preparation of amidoalkyl naphthols employing a multi-component, one-pot condensation reaction of β -naphthol, aromatic aldehydes and acetamide in the presence of ferric hydrogensulfate under solvent, solvent-free and microwave conditions is described. The thermal solvent-free and microwave green procedures offer advantages such as shorter reaction times, simple work-up, excellent yield and recovery and reusability of catalyst. It is noteworthy that 1-amidomethyl-2-naphthols can be converted into important biological 'drug like' active 1-aminomethyl-2-naphthol derivatives by amide hydrolysis.

$$X \xrightarrow{\text{II}} + OH \xrightarrow{\text{Pe}(\text{HSO}_4)_3 \text{ (Catalyst)}} OH \xrightarrow{\text{NH}} VH = H, \text{ CI, F, OMe, NO}_2, \text{ Me}$$

Method A: CH₃CN (Ritter type reaction)
Method B: CH₃CONH₂ (Thermal Solvent-Free conditions)
Method C: CH₃CONH₂ (Microvawe Solvent-Free conditions)

2-Substituted 4-, 5-, and 6-[(1E)-3-oxo-3-phenylprop-1-en-1-yl]pyridazin-3(2H)-ones and 2-substituted 4,5-bis[(1E)-3-oxo-3-phenylprop-1-en-1-yl]pyridazin-3(2H)-ones as potent platelet aggregation inhibitors: Design, synthesis, and SAR studies

pp 793-797

Caroline Meyers, Matilde Yáñez, Abdelaziz Elmaatougi, Tom Verhelst, Alberto Coelho, Nuria Fraiz, Guy L. F. Lemière, Xerardo García-Mera, Reyes Laguna, Ernesto Cano, Bert U. W. Maes and Eddy Sotelo*

Evaluation of a series of bicyclic CXCR2 antagonists

pp 798-803

Iain Walters,* Caroline Austin, Rupert Austin, Roger Bonnert, Peter Cage, Mark Christie, Mark Ebden, Stuart Gardiner, Caroline Grahames, Steven Hill, Fraser Hunt, Robert Jewell, Shirley Lewis, Iain Martin, David Nicholls and David Robinson

The SAR of a series of pyrimidine-based fused bicyclic heterocycles at the CXCR2 receptor was investigated, leading to the discovery of a series of potent, bioavailable thiazolo[4,5-d]pyrimidine-2(3H)-one antagonists 30a-f with additional CCR2 activity.

A very simple synthesis of GlcNAc- α -pyrophosphoryl-decanol: A substrate for the assay of a bacterial galactosyltransferase

pp 804–807

Inka Brockhausen, E. Andreas Larsson and Ole Hindsgaul*

A novel bicyclic hexapeptide, RA-XVIII, from *Rubia cordifolia*: Structure, semi-synthesis, and cytotoxicity

pp 808-811

Ji-Ean Lee, Yukio Hitotsuyanagi, Ik-Hwi Kim, Tomoyo Hasuda and Koichi Takeya*

MeO
$$\frac{R^2}{Me}$$
 $\frac{H}{N}$ $\frac{H}{N}$

2-Aminoresorcinol is a potent α -glucosidase inhibitor

pp 812-815

Hong Gao and Jun Kawabata*

The 2-aminoresorcinol moiety of 6-amino-5,7-dihydroxyflavone (2) is important to exert the α -glucosidase inhibitory activity and 2-aminoresorcinol (4), itself, is a potent α -glucosidase inhibitor.

Chemotherapeutic bone-targeted bisphosphonate prodrugs with hydrolytic mode of activation

pp 816-820

Rotem Erez, Sharon Ebner, Bernard Attali and Doron Shabat*





Synthesis and evaluation of a γ -lactam as a highly selective EP₂ and EP₄ receptor agonist

pp 821-824

Yufang Xiao,* Gian Luca Araldi, Zhong Zhao, Adulla Reddy, Srinivasa Karra, Nadia Brugger, David Fischer, Elizabeth Palmer, Bagna Bao and Sean D. Mckenna

 γ -Lactam analogs (2) of EP₄ receptor agonists were identified by substitution of the pyrazolidinone ring (1) with a pyrrolidinone ring. Several compounds (such as 2a, 2h) with high potency, selectivity, and acceptable PK profiles were discovered. These were assessed in animal models of ovulation induction and bronchoconstriction.

Design and synthesis of a fluorescent muscarinic antagonist

pp 825–827

Lyn H. Jones,* Amy Randall, Carolyn Napier, Mike Trevethick, Sasha Sreckovic and Jessica Watson


The design and concise synthesis of a potent and fluorescent BODIPY-tolterodine conjugate antimuscarinic probe is reported.

New polyphenols active on β -amyloid aggregation

pp 828-831

Céline Rivière, Tristan Richard, Xavier Vitrac, Jean-Michel Mérillon, Josep Valls and Jean-Pierre Monti*

Four novel polyphenols could be efficient fibril inhibitors in Alzheimer's disease: malvidin and its glucoside and curculigosides B and D. Moreover, molecules with the particular C_6 -linkers- C_6 structure could be potent inhibitors.




	\mathbb{R}^1	\mathbb{R}^2	\mathbb{R}^3	
12	OMe	Н	OH	curculigoside A
13	OH	Н	OH	curculigoside B
14	OMe	OH	Н	curculigoside D

Synthesis and evaluation of novel chromogenic peptidase substrates based on 9-(4'-aminophenyl)-10-methylacridinium salts as diagnostic tools in clinical bacteriology

pp 832-835

Rosaleen J. Anderson,* Paul W. Groundwater, Yongxue Huang, Arthur L. James, Sylvain Orenga, Annette Rigby, Céline Roger-Dalbert and John D. Perry

The synthesis and evaluation of novel chromogenic peptidase substrates 4a-g with good species specificity are described.



Carbonic anhydrase inhibitors: Copper(II) complexes of polyamino-polycarboxylamido aromatic/heterocyclic sulfonamides are very potent inhibitors of the tumor-associated isoforms IX and XII

pp 836-841

Marouan Rami, Jean-Yves Winum,* Alessio Innocenti, Jean-Louis Montero, Andrea Scozzafava and Claudiu T. Supuran*

Inhibiting dihydrodipicolinate synthase across species: Towards specificity for pathogens?

pp 842-844

Voula Mitsakos, Renwick C. J. Dobson, F. Grant Pearce, Sean R. Devenish, Genevieve L. Evans, Benjamin R. Burgess, Matthew A. Perugini, Juliet A. Gerrard and Craig A. Hutton*

Inhibitors of dihydrodipicolinate synthase (DHDPS), a key enzyme in lysine biosynthesis and an important antibiotic target, display significant species-specificity.

Antitumor effects of curcumin and structurally β -diketone modified analogs on multidrug resistant cancer cells

pp 845-849

Daniele Simoni,* Michele Rizzi, Riccardo Rondanin, Riccardo Baruchello, Paolo Marchetti, Francesco Paolo Invidiata, Manuela Labbozzetta, Paola Poma, Valeria Carina, Monica Notarbartolo, Alessandra Alaimo and Natale D'Alessandro


Porphyrin conjugated to DNA by a 2'-amido-2'-deoxyuridine linkage

pp 850-855

Sarita Sitaula and Scott M. Reed*

Synthesis, SAR, and antibacterial activity of novel oxazolidinone analogues possessing urea functionality pp 856–860

- N. Selvakumar, * G. Govinda Rajulu, K. Chandra Shekar Reddy, B. Chandra Chary, P. Kalyan Kumar,
- T. Madhavi, K. Praveena, K. Hari Prasada Reddy, Mohammed Takhi, Arundhuti Mallick,
- P. V. S. Amarnath, Sreenivas Kandepu and Javed Iqbal



The syntheses of a series of novel oxazolidinone analogues possessing an urea functionality are reported. The SAR around the urea functional group resulted in interesting antibacterial compounds.



OTHER CONTENTS

Summary of instructions to authors

рI

- *Corresponding author
- **D+ Supplementary data available via ScienceDirect

COVER

Overlay of high resolution co-crystal structures of *R*-22-ADP (cyan) and 1-ADP (green) bound in an allosteric binding site of the mitotic kinesin KSP. [Roecker, A. J.; Coleman, P. J.; Mercer, S. P.; Schreier, J. D.; Buser, C. A.; Walsh, E. S.; Hamilton, K.; Lobell, R. B.; Tao, W.; Diehl, R. E.; South, V. J.; Davide, J. P.; Kohl, N. E.; Yan, Y.; Kuo, L. C.; Li, C.; Fernandez-Metzler, C.; Mahan, E. A.; Prueksaritanont, T.; Hartman, G. D. *Bioorg. Med. Chem. Lett.* 2007, *17*, 5677.]

Indexed/Abstracted in: Beilstein, Biochemistry & Biophysics Citation Index, CANCERLIT, Chemical Abstracts, Chemistry Citation Index, Current Awareness in Biological Sciences/BIOBASE, Current Contents: Life Sciences, EMBASE/Excerpta Medica, MEDLINE, PASCAL, Research Alert, Science Citation Index, SciSearch, TOXFILE



ISSN 0960-894X